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ABSTRACT
Background Gene therapies have the potential 
to be a curative approach to a large number of 
genetic diseases. However, granting of a positive 
marketing authorisation does not equal patient 
access to therapy.
Objectives The purpose of this paper is 
to identify a full set of hurdles potentially 
preventing patient access to gene therapies 
based on the available literature.
Methods A review of the literature using 
systematic approach in two distinct databases 
was performed by identifying relevant, peer- 
reviewed publications, between 2012 and 2018.
Results Seven major topics were identified 
as potential patient access hurdles, namely 
affordability, assessment of value, development 
of therapy, ethical/social factors, evidence 
generation, operational implementation and 
regulatory hurdles. From these, 25 additional 
subthemes were further identified. The most 
frequently mentioned obstacle in the literature 
is related to the affordability aspect especially 
focusing on high cost of therapy (84%) and 
therapy payment/reimbursement (51%). 
Importantly, the evidence generation focusing on 
limited trial outcomes (81%) seems as a strong 
obstacle in patient access to these therapies.
Conclusions A growing number of gene 
therapies are expected to be developed and 
made available to patients and healthcare 
professionals. Improvement of patient access 
to gene therapies can only be achieved by 
understanding all hurdles, in a complete and 
integrated fashion, so that strategies are timely 
established to ensure gene therapies’ benefits 
are provided to patients and to the society.
INTRODUCTION
Gene therapy medicinal products 
(GTMPs) are exceptionally promising 
treatment strategies, with the potential 
to cure a wide array of genetic diseases.1 
Extensive research has been conducted in 
the field. According to Hanna et al, the 
number of clinical trials using GTMP as 
medicinal product has increased steadily 
over the past few years.2
This trend is aligned with the growing 
number of commercialised GTMPs 
worldwide. In Europe, the first GTMP 
approved was Glybera, in 2012. Since 
then, and until end of 2019, six additional 
products reached a positive marketing 
authorisation outcome (Imlygic, Strim-
velis, Kymriah, Yescarta, Luxturna and 
Zynteglo). Conversely, in the USA, the 
first GTMP reached the market in 2017, 
while in the same time period a total of 
five approved products (Imlygic, Kymriah, 
Yescarta, Luxturna and Zolgensma) 
GTMPs are available.3 4
Development of GTMPs is a chal-
lenging process. Our previous research 
suggests that the main driver for nega-
tive marketing authorisation outcome 
in Europe is insufficient clinical efficacy 
evidence as well as safety issues, while 
issues at quality or non- clinical level play 
a secondary role in marketing authorisa-
tion application (MAA) outcome.5 Regu-
lators are aware that advanced therapy 
medicinal products (ATMPs) aim at 
diseases of high unmet medical need. 
Therefore, in Europe, several strategies 
have been implemented to expedite the 
MAA process, such as the implementation 
of the innovative task force, the ATMP 
classification, the ATMP certification, the 
PRIority MEdicines scheme and scientific 
advice.1 5
However, a positive MAA outcome 
should not be considered an imme-
diate synonym of therapy availability 
to patients. In Europe, after regulatory 
approval, health technologies are assessed 
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for their value with subsequent (or parallel) pricing 
and reimbursement negotiations.6 In the case of gene 
therapy, this aspect is of particular importance consid-
ering the significant budget impact in health systems 
that GTMPs may elicit. Although high cost and budget 
impact are undoubtedly critical aspects in patient access 
to innovative therapies, additional factors should be 
taken into account.
This research intends to provide a comprehensive 
review of patient access to gene therapy by identifying 
a full set of hurdles. A review of the literature using 
systematic approach in two distinct databases was 
performed to identify relevant, peer- reviewed publi-
cations, between the years of 2012 and 2018. Data 




The Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses (PRISMA) guidelines for 
conducting systematic reviews were followed. This 
study included publications available in Medline 
(accessed via PubMed) and Embase (accessed via Ovid) 
published between 1974 and 20 January 2019. The 
search strategy was purposefully designed to be broad, 
in order to ensure all relevant material was included.
Our search included both mapped and unmapped 
terms. Within the conducted search, “Boolean Oper-
ator” rules were used. The terms used were searched 
using ‘AND’ to combine the keywords listed and using 
‘OR’ to remove search duplication where possible. 
Full search strategy is available as online supplemental 
appendix 1.
The process of identification, screening and inclu-
sion of papers for this review is detailed in figure 1. 
Records were extracted to EndNote V.X8. The soft-
ware deduplication functionality was used to identify 
duplicate references. Additionally, manual deduplica-
tion was performed. Following full text review, refer-
ences were further excluded based on eligibility criteria 
described in table 1.
Publication selection
Eligibility criteria were developed in order to reflect 
the research aim. First, papers were included if they 
were published between 2012 and 2018. The year of 
2012 was selected as lower cut- off date as it was the 
year that the first GTMP was approved in Europe. 
Only full- text articles published in peer review jour-
nals were included.
Articles which referred to the topic including but not 
limited to GTMP were included as well. This means 
that if a paper discussed cell and gene therapy simulta-
neously, this publication was included in the analysis. 
Additionally, at least one challenge related to patient 
access had to be extracted from the full- text review, in 
order to include the publication in the analysis.
Publications were excluded if not written in English. 
Other publication types such as books, book chapters, 
news articles/press release, and congress abstracts/
posters were excluded. Eligibility criteria are fully 
detailed in table 1.
Data extraction and analysis
Publication characteristics were extracted from all rele-
vant articles and were recorded in an extraction table. 
One researcher (MC) compared and extracted data and 
discussed any discrepancies with other researchers (BS, 
APM), when required. An overview of the identifica-
tion process is documented in the PRISMA diagram, 
in figure 1.
Hurdles towards patient access were extracted from 
the full- text review of the articles. Major themes and 
subthemes were pulled from the data, until no more 
major topics and subtopics could be identified. Narra-
tive synthesis of the articles was performed. A qualita-
tive and quantitative analysis of the extracted hurdles 
is here presented.
RESULTS
The search in both databases identified 14 123 publi-
cations. After removing 340 duplicates, a total of 7463 
references were excluded based on year and language. 
Then, all remaining titles and abstracts were reviewed 
by MC for relevance, in alignment with the main 
objective of this research project, where 6247 were 
excluded. A total of 73 full text articles were reviewed. 
Studies were excluded if they did not meet the eligi-
bility criteria specified in the study. Twenty- two records 
Figure 1 Process of identification, screening, eligibility and 
inclusion in this comprehensive review. TI/AB: Title/Abstract.
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were excluded based on exclusion criteria 2 (publica-
tion type), 18 records were excluded based on inclu-
sion criteria 4 (main topic) and 1 record was excluded 
based on inclusion criteria 5 (outcome).
In this analysis, 32 publications were included in 
qualitative and quantitative synthesis. These publica-
tions generated 7 major themes with 25 subthemes, 
which are described in table 2.
A frequency graph was generated which presents the 
number of publications out of the 32 which mention a 
specific hurdle, in each subtheme (figure 2).
The six most common hurdles found in this compre-
hensive review belong to the themes/subthemes 
described below:
 ► Twenty- seven publications (84%) mentioned afforda-
bility issues (therapy cost/price).
 ► Twenty- six publications (81%) mentioned evidence 
generation issues (trial outcomes).
 ► Eighteen publications (51%) mentioned affordability 
issues (therapy payment/reimbursement).
 ► Fourteen publications (44%) mentioned operational 
implementation issues (infrastructures).
 ► Eleven publications (34%) mentioned affordability issues 
(payer’s budget).
 ► Eleven publications (34%) mentioned assessment of 
value issues (patient- related health benefits).
Each theme and subthemes are described in more 




The price hurdle is not just related to the excessive 
high cost of these therapies.2 7–25 The price level is 
mainly justified by the high cost of development and 
manufacture.13 Some authors also mention that the 
increased medical follow- up associated with detecting 
late toxicities contributes to added costs.20 26 Further-
more, higher therapy cost is a possibility in special 
scenarios (eg, cost of gene therapy for patients with 
haemophilia who develop some level of immunoge-
nicity, ie, antidrug antibodies is higher).22
On the other hand, many gene therapy products 
were developed using government/public funds. 
However, when setting up the final price, this is not 
taken into account.10 26 Estimating annual and lifetime 
costs is challenging due to variability in disease presen-
tation, type, frequency of treatments required, access 
to follow- up care and payer source.21
Payer’s budget
Such an elevated price clearly has a significant impact 
on the healthcare budget impact.2 10 13 15–17 20 25 27 For 
example, in the USA, it is estimated that 25–30 million 
Americans have a rare condition related to a genetic 
defect. Considering the initial pricing experience with 
Table 1 Study inclusion and exclusion criteria
Number Category Description
Inclusion criteria
IC-1 Publication year 2012–2018
IC-2 Publication type Full- text articles in peer review journals
IC-3 Publication quality Full text article should include clear objective, methodology, analysis/discussion, 
conclusion and a defined set of references.
IC-4 Type of medicine Including but not limited to gene therapy
IC-5 Outcomes Full text article should include at least one challenge related to patient access
Exclusion criteria
EC-1 Language Articles not in English
EC-2 Publication type Book, book chapters, News articles/press release, congress abstracts/posters






Assessment of value Criteria
Non- patient related health benefit
Patient- related health benefits





Ethical/social factors Patient's convictions
Patient's perception
Socioeconomical















ebruary 16, 2021 at U







J Innov: first published as 10.1136/bm





126 Carvalho M, et al. BMJ Innov 2021;7:123–134. doi:10.1136/bmjinnov-2020-000425
Health technology assessment
gene therapy in Europe, if more gene therapy products 
are made available at US$1–2 million price, the cumu-
lative budget impact would be substantial and perhaps 
unsustainable. Assuming that gene therapies are devel-
oped to treat only one in 10 patients with a genetic 
condition, the cumulative budget impact at that price 
could rise to US$3 trillion, which is as much as the 
current spent in a year on all healthcare in the USA.28
Hurdles at the level of payer’s budget are even 
more marked considering the high pressure to control 
healthcare budget.13 20 This is especially true consid-
ering, for instance, in Europe, the period of recovery 
after a financial crisis and flattening of gross domestic 
product growth.2 In March 2017, a budget impact test 
was introduced in England, which assesses whether a 
new therapy’s aggregate additional cost to the health-
care budget exceeds the threshold value of £20 million 
per year. If the additional cost associated with the new 
therapy is expected to exceed this threshold in any of 
the first 3 years after launch, then additional commer-
cial negotiations and potential restrictions apply.17
Therapy payment/reimbursement
Some authors mentioned the heterogeneity in reim-
bursement/payment strategies across different coun-
tries that geographically lead to different levels of 
access.10 27 It was clear from our research that standard 
reimbursement strategies may not be adequate to cope 
with super high cost treatments.10 13 14 21 Moreover, 
the reimbursement decision takes place after posi-
tive marketing authorisation, and this process may be 
lengthy in some cases.10 Even after the full assessment, 
health insurers may refuse to reimburse therapy. Some 
publications mentioned a lack of willingness to pay 
from governments and payers leading to no reimburse-
ment after approval.19 22 26
An issue occurring particularly in the USA is related 
to the uncertainty on how to manage patients switching 
health plans. The first insurance company may be 
stuck with full upfront payment and no downstream 
benefit in case the patient decides to switch insurance 
company.10 12 21
With regards to discount rates, it is not clear how to 
reach the appropriate discounting rate. Gene therapies 
are likely to involve high intervention costs occurring 
years before all health effects have emerged.15
Finally, in case a payment based on performance is 
implemented, there is uncertainty on which outcomes 
to monitor. Hard endpoints are preferred, though this 
may not be possible in all cases.10
Assessment of value
Criteria
Heterogeneity in value assessment systems across 
different countries results in different coverage recom-
mendations based on how health technology assessment 
(HTA) agencies perceive evidence and uncertainties. 
These different recommendations clearly lead to 
different levels of patient access to therapy. Addition-
ally, several publications reported that gene therapy 
products may be assessed by HTA agencies using the 
same criteria and scrutiny than other classic therapies, 
which may be inadequate, considering the specifici-
ties of gene therapy. HTA systems appear to not be 
prepared to assess curative therapies.15 16 21 23 28 29
Non-patient-related health benefits
Some publications included in this analysis also high-
lighted that HTA models may not account for all 
Figure 2 Frequency of factors identified to influence patient access to gene therapy.
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relevant elements for assessment of value for health 
system and society. For instance, the ability of patients 
to go back to work, the work productivity or the 
impact on caregiver burden are often not considered 
for treatment reimbursement.15 21 22 27 28
Patient-related health benefits
A number of publications included in this analysis 
highlighted that endpoints that matter to patients (eg, 
quality of life) are not aligned with efficacy outcomes 
for reimbursement (eg, disease survival). There seems 
to be a strong mismatch between payers’ and regula-
tor’s needs.10 14–16 21 23 26 This divergence may lead to 
a drug being approved by the health authorities for 
commercialisation but not reimbursed and, therefore, 
with a low level of market uptake.
Similarly to the issues noted at the level of non- 
patient- related health benefits, some publications 
reported that HTA models may not account for 
all relevant elements for assessment of value for 
patients.15 21 22 28 For instance, most gene therapies 
have the potential to be curative therapies. These may 
be valued more highly by society as opposed to non- 
curative therapies. Cure of a disease at a young age 
could help produce significant gains in many aspects 
such as omitting the cost of avoidable comorbidi-
ties, lifelong management of complications but also 
reducing the economic impact over individual patients 
and their caregivers/families (ie, work productivity) 
compared with treatments that bring marginal gains 
over many years. There is little evidence that such 
balance is currently being included in HTA.22 28
Development of therapy
Intellectual property
It is know that the academia plays a strong role in 
the development of gene therapy products. A survey 
conducted in 2016 reviewed ATMPs clinical trials 
in the EU reported that the majority of the sponsors 
(62%) were non- profit organisations, representing 
academia, hospitals and charities.30 GTMP develop-
ment is often initiated at the academic level and then 
leveraged by larger pharmaceutical companies after 
commercial agreements are established.
The academia/industry partnerships influence 
remains uncertain, as the merger of academic intellec-
tual freedom with big business focuses on value will 
surely create conflict.29 31 If these divergences remain 
unresolved or take too long to reach a solution, this 
may impact patient access to GTMPs.
Manufacturing
Another issue, particularly regarding gene therapy 
products based on genetic cell modification (eg, 
chimeric antigen receptor (CAR) or T- cell receptor), is 
related to the composition of the cell product. Uncer-
tainties remain regarding the content of drug product/
drug substance. On drug development, investigators 
question which subtypes of cells should be included. 
The selection of specific cell subtypes may increase 
even more the manufacturing costs, impacting patient 
access. The choice of cells is key for therapy success. 
Additionally, how to measure such success may pose 
challenges. Currently, high uncertainty exists regarding 
therapeutic success biomarkers. Without measurable 
efficacy biomarkers, the therapy will never reach the 
patients.31
Non-clinical
During gene therapy development process, animal 
testing is key for advancing to clinical trials. This is 
a challenging process and lack of appropriate non- 
clinical testing may have a therapy fail before even 
reaching to first- in- human studies. Understanding 
cross- species variability, particularly regarding viral 
vectors tropism and transduction efficiency, is critical 
for predicting clinical outcomes. Appropriate devel-
opment of validated preclinical assays will be key to 
clinical experience.29
Positioning
External competitive landscape may have a significant 
impact on GTMP development with consequences to 
patient access. For instance, in the case of haemophilia, 
if the companies that bring GTMPs to market already 
have traditional haemophilia products within their 
portfolio, their incentive to offer gene therapy for a 
low price may be lacking because the new technology 
would disrupt their existing market.22
Another example is the ongoing innovation on 
regular monoclonal antibody therapy that can directly 
compete with antibody gene therapy. The classic 
therapy is a less costly alternative, with less administra-
tion burden and may potentially have higher efficacy.32
Resources
The resources level at the developer may also be a 
key factor influencing patient access. As previously 
mentioned, development of gene therapy often starts 
in non- profit organisations. In our research, some 
authors noted the lack of manufacturers experience2 33 
as well as lack of preparedness from market access 
strategy and launch sequence,2 as key aspects impacting 
patient access. Additionally, low resources for transla-
tional research from academia and early clinical trials29 
and lack of reimbursement after approval may lead 




Core individual values and beliefs may influence 
whether patients’ choose to have GTMP treatment 
or not. In two publications, it was noted that some 
patients may be unwilling to receive GTMPs, for 
instance, due to religious beliefs.34 35 Other patients 
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may be intrinsically against germline genome manip-
ulation, thereby refusing treatment.9 Finally, a study 
showed that one of the biggest fears about receiving 
gene therapy was that patients would not receive all 
the information. This apprehension is directly related 
to the assumption that gene therapy may alter features 
such as identity and personality.35
Patients’ perception
Patients’ perceptions on gene therapy may play a 
powerful role in the level of access to therapy. Several 
publications highlight a general lack of genetic literacy, 
not only from patients but also from caregivers,24 25 36 37 
which in turn contributes to an inaccurate perception 
of gene therapy. In one publication, the potential irre-
sponsible use of novel technologies and unrealistic 
expectation of cure (eg, in the case of HIV) were also 
noted as a barrier related to patients’ perception.8 
Furthermore, the fear that genetic therapy will be used 
by those with means to improve intellect, physical abil-
ities and longevity, thereby enhancing social inequality 
was also noted as a potential access barrier.11 35
Additionally, patients may be unwilling to receive 
genetic therapy due to psychological challenges (eg, 
receiving news about testing positive for a genetic 
marker of disease).34
Finally, a study showed that the degree of gene 
therapy acceptance by the public is directly related 
with the seriousness of the condition. If the disease 
is very serious, then patients will be more willing to 
accept GTMP treatment.35
Socioeconomical factors
Socioeconomical, cultural and geographical factors 
may potentially restrict access to gene therapy. 
Different price setup according to geographical regions 
will result in different GTMP availability. Conse-
quently, others may become ‘treatment tourisms’. 
Finally, according to geographical region, there may 
be differences in standard of care therapy cost. These 
differences lead to different comparisons and conclu-
sions on gene therapy reimbursement, which may 
cause discrepancies in patient access.8 10 11 22 24 25 27 34 38
Evidence generation
Trial design
A USA publication by Hampson et al reported the 
implementation of fully blinded, placebo controlled 
studies with specific GTMPs, in specific indications, 
would require unethical sham procedures13 (i.e. those 
GTMPs that require invasive methods of administra-
tion like Glybera, where the patient is administered 
with multiple intramuscular injections).
Furthermore, challenges at the level of comparator 
identification have been reported. Here, those ther-
apies developed for diseases where there is no treat-
ment are the most affected.13 15 21 In many cases, there 
is no other choice but to assess data resulting from 
single- arm, open label or even observational studies, 
which are known to be less robust for benefit–risk 
evidence generation.
Finally, finding easily measured patient- centred 
outcomes to assess efficacy was reported as an important 
hurdle related to clinical trial design. Trials evaluating 
gene therapy may rely on surrogate outcomes, as 
opposed to clinical outcomes. For instance, in oncology 
setting, the use of data from progression free survival 
as a surrogate endpoint rather than data from overall 
survival as a clinical endpoint allows implementation 
of shorter duration trials, contributing to a more expe-
dited regulatory assessment of a marketing authorisa-
tion. On the other hand, other less known surrogate 
endpoints may be used and, in that case, these need 
to be developed and validated, with limited data and 
limited time.
Weighing up the benefits and risks of any medicine 
is a complex process, as it involves the evaluation of a 
large amount and diverse type of data. The actual bene-
fits and risks of any medicine are determined based 
on the information that is available at a given point in 
time, which often involves a fair level of uncertainty.
In case surrogate endpoints are used, frequently 
there is considerable uncertainty because these may 
not allow capturing the combined benefit–risk profile 
of a technology and a surrogate may not translate to 
benefits for a clinical endpoint.13 15
Trial conduct
With regards to clinical trial conduct, four publications 
reported that getting patients diagnosed and recruited 
into clinical trials, as well as promoting adherence to 
medical follow- up, is an important hurdle. Patients 
seems to be inherently reluctant to share their data and 
participate in clinical translation.13 15 25 26 This may 
potentially be related to patient’s limited knowledge 
of GTMPs. A study on patient’s perspectives regarding 
gene therapy for sickle cell disease reported lack of 
knowledge of gene therapy from patients (eg, patients 
had fear of getting HIV if the vector was based on 
inactivated HIV virus) and a perception that treatment 
with gene therapy would be unacceptably unsafe (ie, 
negative effects of concomitant chemotherapy in sickle 
cell gene therapy, potential new onset of cancer due to 
gene therapy, potential infertility problems).39
Trial outcomes
On reviewing the data generated through pivotal 
clinical trials, some hurdles have been identified 
which could potentially be an obstacle to patient 
access. First, a strong uncertainty related to safety 
data, whether short, medium or long term has been 
reported.13 15 21 23 29 31 32 For instance, for CAR- T 
gene therapy product Yescarta, a number of patients 
experienced citokine release syndrome (CRS) and 
unexplained neurotoxicity. CRS symptoms ranged 
from fever and myalgias to life- threatening unstable 
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hypotension and respiratory failure. While treat-
able for most cases, fatalities have been reported. On 
the other hand, the use of integrating vectors has an 
inherent potential genotoxicity risk, which is of partic-
ular importance following past reports that primary 
immunodeficiency children treated with retroviral 
vectors developed cancer.
Additionally, uncertain long- term efficacy of gene 
therapy products has been reported as a hurdle in 
patient access by several authors.13 16–18 25 27 29 32 On 
one hand, most of the clinical trials for candidate new 
GTMPs are conducted in a limited patient popula-
tion (ie, rare diseases) where the main clinical efficacy 
endpoint is fairly new to the regulators and scientific 
community. These endpoints may not be the best 
choice, but this only becomes clear after some time, 
based on the evolution of knowledge around the 
disease. A great example of this was the European 
regulatory assessment of Glybera, where the initially 
assessed primary endpoint was triglyceride reduction 
but later it was noted that this surrogate endpoint was 
too variable from patient to patient and postprandial 
chylomicron reduction was used instead. On regula-
tory approval, long- term efficacy is extrapolated from 
pivotal clinical trials and when such uncertainty is 
raised at the pivotal trial level, it is even more difficult 
to predict effectiveness.
Moreover, the durability of clinical effect remains 
questionable. On one hand, this may be due to the 
unpredictability of transgene expression. Immunoge-
nicity may limit a prolonged expression, which could 
potentially be related to a decreased clinical effect. On 
the other hand, tissue targeting refinement may be 
needed to improving transduction efficiency.32
Based on the way trials are designed and conducted 
(limited patient population, limited follow- up time, 
limited experience in primary clinical efficacy/safety 
endpoint analysis) it becomes clear that both efficacy 
and safety evidence at launch may be extremely imma-
ture. This may have an impact on limiting therapy 
access to patients.2 10 13–15 17 20 21 23 24
Overall, there is the need for improved under-
standing of the role of specific disease factors in gene 
therapy outcomes. As time goes by, more knowledge 
is built, leading to a better selection of patient popula-
tion, biomarkers and endpoints.29
Post authorisation
After regulatory approval, post authorisation data 
are a mandatory requirement not only for safety but 
also for effectiveness new drug monitoring. Securing 
drug reimbursement is also often based on obtaining 
real world evidence. This is particularly important 
for GTMPs, where approval/reimbursement may be 
obtained with incredibly limited number of patients 
and open- label, uncontrolled clinical trials.15–17 27
In some instances, there is the need of implementing 
a patient registry. Several challenges related to this 
method of collecting postauthorisation data have been 
reported,10 40 including but not limited to:
 ► Low number of patients.
 ► Long term follow- up which may lead to low retention 
rate.
 ► High administrative burden (eg, establishing site contract, 
local ethics committee approval, site staff training, etc).
 ► High associated costs (eg, registry oversight, costs associ-
ated with multiple sites, database set- up, etc).
 ► Limited data quality (eg, who is contributing to the 
registry, that is, only physicians? Patients? Family/
caregivers?).
 ► Limited resources (eg, regulatory agencies often approve 
gene therapy conditional to the implementation of a 
disease registry. From an industry perspective, sponsors 
prefer a registry based on drug use, while regulatory 
agencies favour a broader disease- based registry).
 ► Data privacy issues (eg, in USA, if reimbursement is 
based on implementation of a patient registry, the legis-




Gene therapy manufacturing and quality control 
process are lengthy and complex (eg, difficulty in 
large- scale production of clinical- grade vectors). 
Besides not being readily available, certain GTMPs 
have generally short shelf- life, which may be particu-
larly challenging in cases of urgent need of therapy (eg, 
acute diseases).7 15 29
Access to therapy may also be influenced by the need 
for adequate healthcare infrastructures regarding gene 
therapy manufacturing, administration and pre/post-
administration medical monitoring.8–10 13 16 20 23 24 38 
One publication reported that major health system 
changes are required before gene therapy can be fully 
implemented, highlighting the current limitations in 
information technology systems and limited support 
tools for clinical use of the information.37
Finally, many therapies in precision medicine, and 
especially gene therapy, need to have an appropriate 
validated companion diagnostic test approved by regu-
latory agencies, which the availability may differ from 
country to country.25
Patient burden
Generally, gene therapy administration involves a 
heavy patient burden.7 16 Patients need to be hospital-
ised to receive therapy. The hospitalisation may be for a 
variable period of time, since it may also include either 
preadministration preparation and/or postadministra-
tion medical monitoring. The majority of traditional 
drugs are self- administered by the patient, or even 
administered by a close caregiver, in the comfort of 
their home environment. For the case of gene therapy, 
due to its unique characteristics, administration in the 
hospital setting is likely to be the rule. Here, one should 
take the patient’s perspective where an additional itin-
eration from patient’s home to a specific healthcare 
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facility (in this case, hospital setting) could potentially 
be a hurdle for patient access, in many aspects, such as 
additional time spent or additional resources. Strimv-
elis is an example of gene therapy administered only at 
one site in Italy, meaning that patients have to travel to 
that specific clinical setting to receive treatment.
Healthcare professionals
As a unique and very distinctive therapeutic strategy, 
compared with classic treatments, gene therapy 
requires formal healthcare professional training (eg, 
with regards to safety and rescue therapy should any 
life- threatening toxicity occur).7 8 10 15 16 21 37 Also, 
physicians should be adequately trained to clearly 
explain patients and caregivers the benefits and risks25 
of gene therapy.
Finally, a higher than usual administrative burden 
is expected for gene therapy,20 related to electronic 
patient medical records completion by healthcare 
professionals as well as other administrative documents 
(eg, health insurance forms). Overall, the specific 
training and higher administrative burden will likely 
result on an increase in human resource workload.
Regulatory hurdles
Marketing authorisation application process
Hurdles related to MAA process have been identified to 
contribute to different levels of patient access to gene 
therapies. First, there is a lack of regulatory harmonisa-
tion regarding ATMPs definition.33 In Europe, the defi-
nition of ATMP is included in regulation 1394/2007/
EC. However, when a sponsor requests a classification 
from the European Medicines Agency (EMA), this it is 
not legally binding, and each member state may clas-
sify the same product differently.
Additionally, there is a lack of regulatory harmoni-
sation towards MAA approval resulting in a different 
number of approved ATMPs across different 
geographical regions. For instance, up to 2017, in 
Europe there were 9 cell and gene therapy products 
approved through centralised procedure, while in the 
USA there were 17 products.41 From a patient access 
perspective, this may generate differences in accessing 
treatment according to geographical region. Legisla-
tive flexibility exists in different jurisdictions, specifi-
cally created to facilitate access to therapy for products 
not yet centrally authorised, although this means addi-
tional time and resources spent.
One publication specifically focusing on academic 
developers also reported the lack or limited interac-
tion with regulators which decreases chances of a posi-
tive MAA.33 In Europe, several regulatory strategies 
are currently in place to support new ATMPs early 
in the development process, such as requesting for 
scientific advice/protocol assistance (SA/PA). A recent 
study conducted by Bravery et al42 analysed the first 
22 ATMP MAA submissions to the EMA suggests 
that requesting SA/PA does not seem to be decisive in 
terms of successfully obtaining MAA, since all spon-
sors requested it. Large pharmaceutical companies 
requested more SA/PA compared with small–medium 
enterprises, where academic developers are included. 
On one hand, the initiative to request SA/PA comes 
primarily from the applicant, as well as the content of 
the advice that is sought. It seems fundamental to ask 
the right questions, on the right timing. In addition, 
and although it may be unexpected, non- compliance 
with the regulator’s advice can be accepted in some 
cases. For instance, for Imlygic, advice was sought 
regarding the primary endpoint. While the EMA 
advised to use progression- free survival or overall 
survival, the applicant decided to use durable response 
rate, which was considered acceptable by the EMA, 
with proper justification.
Finally, two publications highlighted the lack of reim-
bursement after approval which may cause withdrawal 
of MAA.17 41 For instance, in Europe, the sponsor of 
Provenge (Sipoleucel- T) requested withdrawal of MAA 
in May 2015. The MAA of Glybera (Alipogene tipar-
vovec) expired in October 2017 and the sponsor chose 
not to review it due to commercial reasons.
Quality standards
Academic centres are important contributors to GTMP 
development. A study by Pearce et al33 has shown 
several interesting barriers at the level of quality stan-
dards that may have an impact on patient access. First, 
even though it is considered an essential process, GMP 
manufacture adds significant costs and complexity to 
the production process. Second, there are unrealistic 
expectations of product qualification by some national 
health authorities in terms of manufacturing process. 
Lastly, in the EU, there is the statutory requirement 
for a qualified person (QP) for the release of investi-
gational medicinal products. QP release of each batch 
when a single batch treats a single patient is prohibi-
tively expensive and may even be logistically impos-
sible in some cases.
Pricing regulations
While there are heterogeneous pricing regulations 
across different geographical areas, it is clear that 
GTMPs with elevated price will increase financial 
pressure on healthcare budget. Payers are less and less 
willing to pay for therapy with immature evidence. 
However, in diseases of high unmet medical need, 
society is likely to exert pressure on politicians to get 
access to therapies. In this context, pricing regula-
tions need to be reconsidered, taking into account the 
growing number of high- cost gene therapy products 
approaching the market.2
Parallel access
In Europe, hospital exemption (HE) is an alternative 
pathway to centralised marketing authorisation. HE 
is a permission that can be granted by EU member 
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states for unauthorised ATMPs to be used on a named- 
patient basis in a hospital setting within the same 
member state only and under the exclusive respon-
sibility of the treating physician. While theoretically 
this should promote patient access to GTMPs, the less 
stringent requirements in HE may put public health at 
risk.26 33 41 For instance, HE has been criticised because 
its implementation varies between member states, 
which has been said to put patients at risk (eg, due to 
nonroutine processing in small batches). In addition, a 
successful pharmaceutical industry’s lobbying resulted 
in attaining such a level playing field (ie, compa-
rable competition environment/setting), in which the 
conditions for applying HE are kept as narrow as 
possible. Consequently, hospitals have more difficulty 
in competing with commercial actors manufacturing 
ATMPs. This has resulted in some valuable established 
therapies risking to become unavailable for patients 
in need of them.41 43 Additionally, the abusive use of 
parallel access pathways may result in withdrawal of 
centralised marketing authorisation.33 41
CURRENT GTMP PATIENT ACCESS LANDSCAPE IN 
EUROPE AND USA
Other authors have attempted to review GTMP reim-
bursement status and HTA decisions in major European 
countries and USA, allowing us to reflect on gene therapy 
patient access in each individual country.44 45 In England, 
two GTMPs were reimbursed (Imlygic, Strimvelis) with 
patient access schemes. In addition, two CAR- Ts (Yescarta 
and Kymriah) were funded through the Cancer Drugs 
Fund.44 45 In Scotland, Kymriah was accepted for B- cell 
acute lymphoblastic leukaemia treatment with a patient 
access scheme, while Yescarta and Kymriah for diffuse 
large B- cell lymphoma were rejected due to unjustified 
cost- effectiveness estimates.44 In Germany, three GTMPs 
had ‘non- quantifiable added benefit’ due to insufficient 
data (Glybera, Yescarta and Kymriah) and Imlygic had 
‘no- added benefit’ due to inappropriate comparator use. 
However, this did not limit its reimbursement.44 45 Three 
GTMPs were reimbursed in France (Yescarta, Kymriah 
and Luxturna), while Glybera was not recommended, as 
it was considered to have ‘insufficient’ benefit due to its 
unsustainable and heterogeneous treatment effects.44 45 
In Italy, one GTMP was reimbursed for hospital use with 
managed entry agreement (Strimvelis).45 In Spain, 
Kymriah was recommended for use inspecialised 
centres.45 In the USA, Kymriah, Yescarta, Luxturna and 
Zolgensma were evaluated as having substantial net 
health benefits. However, a high certainty of conclu-
sion for the assessment of Zolgensma was established44. 
No data on Zynteglo were available for any of the EU5 
countries either because the assessment is in progress or 
not assessed at all.45
Overall, discrepancies among HTA bodies’ perception 
of GTMPs’ value were noticed. Hanna et al highlight 
that uncertainty due to lack of robust and long- term 
evidence was the main limitation in securing reimburse-
ment. On the other hand, conditional reimbursement 
is increasingly considered a useful strategy to mitigate 
uncertainty as it allows collection of long- term data whist 
minimising the impact on patient access. Qiu et al refer 
that although the limitations in pivotal studies resulted in 
substantial uncertainties regarding long- term treatment 
benefit, there was still a possibility for gene therapies to 
gain acceptance from HTA bodies. Most importantly, 
further evidence collection becomes the critical key, not 
only to reduce the uncertainty in reimbursement deci-
sions, but also to increase the public’s confidence in the 
use of gene therapies.
Both these studies results are aligned with the 
present study with special focus on the fact that 
evidence generation (trial outcomes) and affordability 
(reimbursement issues) are two of the most relevant 
hurdles in GTMP patient access. Qiu et al also high-
light that value appreciation constitutes an important 
factor for patient access impacting reimbursement, 
since different countries showed different perspectives 
on the weights allocated to each attribute. In our study, 
the criteria used on value assessment were found in 6 
out of 32 publications (19%).
Neither HTAs nor payers are a homogeneous 
group of decision makers. Different methodologies 
and factors have an impact on the decision process 
depending on these methodological differences, 
thereby influencing patient access to medicines. Char-
acteristics of different payer types are available in 
table 3. Additionally, HTA agencies may be grouped in 
three key archetypes.46 Agencies, such as the German 
IQWiG/G- BA, base their decision on the clinical 
benefit assessment, while cost- effectiveness analysis 
is only conducted in case of disagreements during 
pricing negotiation. Others including the English 
National Institute for Clinical Excellence (NICE) and 
the Scottish Medicines Consortium (SMC), mainly 
base their decisions on cost- effectiveness analysis using 
Table 3 Key payer types
Payer type Description Country
Private insurance markets Free market environment with competing private insurance USA, Switzerland
Therapeutic reference markets Relative therapeutic effectiveness index (demonstrated meaningful benefits 
over comparator)
Germany, France
Cost- effectiveness markets Rigid modelling and value thresholds England
Budget impact markets Cost to system to adopt new therapy Italy, Spain
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the incremental cost- effectiveness ratio. Some ‘mixed’ 
HTA frameworks combine both clinical benefit assess-
ment and health economic assessment when making 
their decisions (cost- effectiveness and budget impact 
analysis). Here, decisions are mainly driven by budget 
impact analysis rather than cost- effectiveness analysis. 
For instance, in Italy and Spain, cost- effectiveness anal-
ysis and budget impact analysis are not mandatory for 
national pricing and reimbursement application, but 
they can be submitted by the manufacturers.47
CONCLUSION
A limited number of GTMPs have successfully been 
granted successful marketing authorisation, in Europe. 
We have previously conducted a retrospective study 
focusing on hurdles that GTMPs face during the MAA 
process. Clinical efficacy and safety issues appeared to 
have a major impact in unsuccessful MAA outcome for 
GTMPs.5 However, a positive MAA does not neces-
sarily mean that the therapy is actually being used by 
patients and healthcare professionals.
From this comprehensive review, seven major themes 
were identified as potential patient access hurdles 
towards gene therapy clinical application and 25 
subthemes were further identified. The major themes 
are outlined below:
1. Affordability.
2. Assessment of value.





Affordability issues especially related to therapy cost/
price (84%) but also to therapy payment/reimburse-
ment (51%) are those most mentioned throughout the 
publications included in this analysis. There is no ques-
tion that providing a potentially curative therapy comes 
at a certain price, most of the times unprecedentedly 
high. Throughout the years, this has not been the case 
for traditional medicines, as often the new products 
are intended to treat rather than cure diseases. Overall 
pressure to control healthcare budget is elevated. The 
assessment of value provides a link between therapy 
benefits for the patient and for the healthcare system 
and the willingness to pay. The payment/reimburse-
ment decision- making process is based on the gener-
ated evidence which often included fairly limited, not 
only in patient numbers but also in the follow- up time, 
as most gene therapy products target rare diseases. This 
uncertainty contributes to different levels of access to 
gene therapy, since with the same data have been noted 
that one product is reimbursed in one country but not 
in another, due to different criteria. Our research results 
seem aligned with other author45 48 in the sense that 
evidence generation (trial outcomes) and affordability 
(reimbursement issues) present two of the most rele-
vant hurdles in GTMP patient access. Additionally, value 
appreciation is noted as an important hurdle for patient 
access impacting reimbursement. HTAs and payers are 
heterogeneous group of decision makers across juris-
dictions and diverse assessment methodologies have an 
impact on the decision process.
The lack of relevant information (comparative data 
vs potential comparators, robust Quality of Life (QoL) 
data, collection of relevant outcomes, short trial dura-
tions) raises high uncertainty regarding the long- term 
efficacy and safety for most gene therapies. HTA bodies 
use different methodologies to minimise this uncertainty 
while accepting high cost GTMPs. Despite this, to date, 
most gene therapies have successfully been granted reim-
bursement, with more or less delay in terms of assess-
ment timelines, as described elsewhere.44
In less extent, ethical and social aspects related to 
the use of genetic therapy also seem to impact patient 
access. It became clear that the more serious a medical 
condition is, the more likely the patient is willing to 
use gene therapy. Operational implementation of 
gene therapy also rises as an important access aspect, 
especially related to the need of having specific infra-
structures for administration of therapy and medical 
follow- up, as well as trained healthcare professionals. 
Some hurdles (eg, patient perception, beliefs. etc) are 
applicable to all patients, regardless of geography.
Society and healthcare systems must adjust to this 
new reality. It is expected in the near future that more 
and more GTMPs are developed and made available 
to patients and healthcare professionals. Improvement 
of patient access and GTMP availability can only be 
achieved by understanding all hurdles, in a complete and 
integrated fashion. It is important to have these hurdles 
present so that clear strategies are set to overcome them 
since the significant benefits of gene therapy will not be 
realised unless patients have access to it.
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Appendix 1 
1.1 Search strategy EMBASE 
 
Database: Embase <1974 to 2019 January 18> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp health care access/ or exp health care delivery/ (2913739) 
2     exp gene therapy/ (78311) 
3     gene therapy.mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, 
candidate term word] (91990) 
4     genetic therapy.mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, 
candidate term word] (575) 
5     viral therapy.mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, 
candidate term word] (1718) 
6     recombinant nucleic acid.mp. [mp=title, abstract, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading 
word, candidate term word] (19) 
7     DNA therapy.mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, 
candidate term word] (47) 
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8     recombinant DNA.mp. [mp=title, abstract, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, 
candidate term word] (23441) 
9     nucleic acid therapy.mp. [mp=title, abstract, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, 
candidate term word] (46) 
10     RNA therapy.mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, 
candidate term word] (107) 
11     Gene Transfer Techniques.mp. [mp=title, abstract, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading 
word, candidate term word] (466) 
12     DNA Viruses.mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, 
candidate term word] (3475) 
13     RNA Viruses.mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, 
candidate term word] (7197) 
14     Genetic Vector.mp. [mp=title, abstract, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, 
candidate term word] (55) 
15     2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 (131367) 
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16     Market.mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, 
candidate term word] (89054) 
17     patient.mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, 
candidate term word] (5159673) 
18     healthcare.mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, 
candidate term word] (328210) 
19     medicines.mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, 
candidate term word] (71975) 
20     drugs.mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, 
candidate term word] (938723) 
21     pharmaceuticals.mp. [mp=title, abstract, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, 
candidate term word] (47428) 
22     16 or 17 or 18 or 19 or 20 or 21 (6180165) 
23     Access.mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, 
candidate term word] (428847) 
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24     availability.mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, 
candidate term word] (245933) 
25     accessibility.mp. [mp=title, abstract, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, 
candidate term word] (45388) 
26     23 or 24 or 25 (686811) 
27     22 and 26 (253478) 
28     1 or 27 (3067123) 
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1.2 Search strategy MEDLINE 
 
("health services accessibility"[MeSH Terms] OR ((((((Market[All Fields] OR ("patients"[MeSH 
Terms] OR "patients"[All Fields] OR "patient"[All Fields])) OR ("delivery of health 
care"[MeSH Terms] OR ("delivery"[All Fields] AND "health"[All Fields] AND "care"[All 
Fields]) OR "delivery of health care"[All Fields] OR "healthcare"[All Fields])) OR ("Medicines 
(Basel)"[Journal] OR "medicines"[All Fields])) OR ("pharmaceutical preparations"[MeSH 
Terms] OR ("pharmaceutical"[All Fields] AND "preparations"[All Fields]) OR "pharmaceutical 
preparations"[All Fields] OR "drugs"[All Fields])) OR ("pharmaceutical preparations"[MeSH 
Terms] OR ("pharmaceutical"[All Fields] AND "preparations"[All Fields]) OR "pharmaceutical 
preparations"[All Fields] OR "pharmaceuticals"[All Fields])) AND ((Access[All Fields] OR 
availability[All Fields]) OR accessibility[All Fields]))) AND (((((((((((("genetic therapy"[MeSH 
Terms] OR ("genetic therapy"[MeSH Terms] OR ("genetic"[All Fields] AND "therapy"[All 
Fields]) OR "genetic therapy"[All Fields] OR ("gene"[All Fields] AND "therapy"[All Fields]) 
OR "gene therapy"[All Fields])) OR ("genetic therapy"[MeSH Terms] OR ("genetic"[All Fields] 
AND "therapy"[All Fields]) OR "genetic therapy"[All Fields])) OR ("oncolytic 
virotherapy"[MeSH Terms] OR ("oncolytic"[All Fields] AND "virotherapy"[All Fields]) OR 
"oncolytic virotherapy"[All Fields] OR ("viral"[All Fields] AND "therapy"[All Fields]) OR 
"viral therapy"[All Fields])) OR (recombinant[All Fields] AND ("nucleic acids"[MeSH Terms] 
OR ("nucleic"[All Fields] AND "acids"[All Fields]) OR "nucleic acids"[All Fields] OR 
("nucleic"[All Fields] AND "acid"[All Fields]) OR "nucleic acid"[All Fields]))) OR ("genetic 
therapy"[MeSH Terms] OR ("genetic"[All Fields] AND "therapy"[All Fields]) OR "genetic 
therapy"[All Fields] OR ("dna"[All Fields] AND "therapy"[All Fields]) OR "dna therapy"[All 
Fields])) OR ("dna, recombinant"[MeSH Terms] OR ("dna"[All Fields] AND "recombinant"[All 
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Fields]) OR "recombinant dna"[All Fields] OR ("recombinant"[All Fields] AND "dna"[All 
Fields]))) OR (("nucleic acids"[MeSH Terms] OR ("nucleic"[All Fields] AND "acids"[All 
Fields]) OR "nucleic acids"[All Fields] OR ("nucleic"[All Fields] AND "acid"[All Fields]) OR 
"nucleic acid"[All Fields]) AND ("therapy"[Subheading] OR "therapy"[All Fields] OR 
"therapeutics"[MeSH Terms] OR "therapeutics"[All Fields]))) OR (("rna"[MeSH Terms] OR 
"rna"[All Fields]) AND ("therapy"[Subheading] OR "therapy"[All Fields] OR 
"therapeutics"[MeSH Terms] OR "therapeutics"[All Fields]))) OR ("gene transfer 
techniques"[MeSH Terms] OR ("gene"[All Fields] AND "transfer"[All Fields] AND 
"techniques"[All Fields]) OR "gene transfer techniques"[All Fields])) OR ("dna viruses"[MeSH 
Terms] OR ("dna"[All Fields] AND "viruses"[All Fields]) OR "dna viruses"[All Fields])) OR 
("rna viruses"[MeSH Terms] OR ("rna"[All Fields] AND "viruses"[All Fields]) OR "rna 
viruses"[All Fields])) OR ("genetic vectors"[MeSH Terms] OR ("genetic"[All Fields] AND 
"vectors"[All Fields]) OR "genetic vectors"[All Fields] OR ("genetic"[All Fields] AND 
"vector"[All Fields]) OR "genetic vector"[All Fields])) 
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